000491342 001__ 491342
000491342 005__ 20250727042326.0
000491342 0247_ $$2doi$$a10.1016/j.bmc.2022.117130
000491342 0247_ $$2ISSN$$a0968-0896
000491342 0247_ $$2ISSN$$a1464-3391
000491342 0247_ $$2datacite_doi$$a10.3204/PUBDB-2023-00097
000491342 0247_ $$2pmid$$a36542958
000491342 0247_ $$2WOS$$aWOS:000911046100001
000491342 0247_ $$2openalex$$aopenalex:W4312095265
000491342 0247_ $$2altmetric$$aaltmetric:166335849
000491342 037__ $$aPUBDB-2023-00097
000491342 041__ $$aEnglish
000491342 082__ $$a610
000491342 1001_ $$00000-0001-6731-5494$$aOrsi, Douglas L.$$b0
000491342 245__ $$aDiscovery and characterization of orally bioavailable 4-chloro-6-fluoroisophthalamides as covalent PPARG inverse-agonists
000491342 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2023
000491342 3367_ $$2DRIVER$$aarticle
000491342 3367_ $$2DataCite$$aOutput Types/Journal article
000491342 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1674650101_7296
000491342 3367_ $$2BibTeX$$aARTICLE
000491342 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000491342 3367_ $$00$$2EndNote$$aJournal Article
000491342 520__ $$aPPAR gamma (PPARG) is a ligand activated transcription factor that regulates genes involved in inflammation, bone biology, lipid homeostasis, as well as a master regulator of adipogenesis and a potential lineage driver of luminal bladder cancer. While PPARG agonists lead to transcriptional activation of canonical target genes, inverse agonists have the opposite effect through inducing a transcriptionally repressive complex leading to repression of canonical target gene expression. While many agonists have been described and tested clinically, inverse agonists offer an underexplored avenue to modulate PPARG biology in vivo. Current inverse agonists lack favorable in vivo properties; herein we describe the discovery and characterization of a series of orally bioavailable 4-chloro-6-fluoroisophthalamides as covalent PPARG inverse-agonists, BAY-5516, BAY-5094, and BAY-9683. Structural studies of this series revealed distinct pre- and post-covalent binding positions, which led to the hypothesis that interactions in the pre-covalent conformation are primarily responsible for driving affinity, while interactions in the post-covalent conformation are more responsible for cellular functional effects by enhancing PPARG interactions with its corepressors. The need to simultaneously optimize for two distinct states may partially explain the steep SAR observed. Exquisite selectivity was achieved over related nuclear receptors in the subfamily due in part to a covalent warhead with low reactivity through an SNAr mechanism in addition to the specificity gained through covalent binding to a reactive cysteine uniquely positioned within the PPARG LBD. BAY-5516, BAY-5094, and BAY-9683 lead to pharmacodynamic regulation of PPARG target gene expression in vivo comparable to known inverse agonist SR10221 and represent new tools for future in vivo studies to explore their potential utility for treatment of disorders of hyperactivated PPARG including luminal bladder cancer and other disorders.
000491342 536__ $$0G:(DE-HGF)POF4-6G3$$a6G3 - PETRA III (DESY) (POF4-6G3)$$cPOF4-6G3$$fPOF IV$$x0
000491342 588__ $$aDataset connected to CrossRef, Journals: bib-pubdb1.desy.de
000491342 693__ $$0EXP:(DE-H253)P-P14-20150101$$1EXP:(DE-H253)PETRAIII-20150101$$6EXP:(DE-H253)P-P14-20150101$$aPETRA III$$fPETRA Beamline P14$$x0
000491342 693__ $$0EXP:(DE-H253)P-P11-20150101$$1EXP:(DE-H253)PETRAIII-20150101$$6EXP:(DE-H253)P-P11-20150101$$aPETRA III$$fPETRA Beamline P11$$x1
000491342 7001_ $$aFerrara, Steven J.$$b1
000491342 7001_ $$00000-0002-4913-1146$$aSiegel, Stephan$$b2
000491342 7001_ $$00000-0002-3912-8162$$aFriberg, Anders$$b3
000491342 7001_ $$aBouché, Léa$$b4
000491342 7001_ $$aPook, Elisabeth$$b5
000491342 7001_ $$00000-0002-6048-4559$$aLienau, Philip$$b6
000491342 7001_ $$00000-0001-9170-5919$$aBluck, Joseph P.$$b7
000491342 7001_ $$00000-0001-9419-1511$$aLemke, Christopher T.$$b8
000491342 7001_ $$aAkcay, Gizem$$b9
000491342 7001_ $$aStellfeld, Timo$$b10
000491342 7001_ $$aMeyer, Hanna$$b11
000491342 7001_ $$aPütter, Vera$$b12
000491342 7001_ $$aHolton, Simon J.$$b13
000491342 7001_ $$00000-0002-6250-6344$$aKorr, Daniel$$b14
000491342 7001_ $$00000-0003-1861-824X$$aJerchel-Furau, Isabel$$b15
000491342 7001_ $$aPantelidou, Constantia$$b16
000491342 7001_ $$aStrathdee, Craig A.$$b17
000491342 7001_ $$aMeyerson, Matthew$$b18
000491342 7001_ $$aEis, Knut$$b19
000491342 7001_ $$0P:(DE-HGF)0$$aGoldstein, Jonathan T.$$b20$$eCorresponding author
000491342 773__ $$0PERI:(DE-600)1501507-5$$a10.1016/j.bmc.2022.117130$$gVol. 78, p. 117130 -$$p117130 $$tBioorganic & medicinal chemistry$$v78$$x0968-0896$$y2023
000491342 8564_ $$uhttps://www.sciencedirect.com/science/article/pii/S0968089622005235?via%3Dihub
000491342 8564_ $$uhttps://bib-pubdb1.desy.de/record/491342/files/Discovery%20and%20characterization%20of%20orally%20bioavailable%204-chloro-6-fluoroi-%20sophthalamides%20as%20covalent%20PPARG%20inverse-agonists.pdf$$yOpenAccess
000491342 8564_ $$uhttps://bib-pubdb1.desy.de/record/491342/files/Discovery%20and%20characterization%20of%20orally%20bioavailable%204-chloro-6-fluoroi-%20sophthalamides%20as%20covalent%20PPARG%20inverse-agonists.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000491342 909CO $$ooai:bib-pubdb1.desy.de:491342$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000491342 9131_ $$0G:(DE-HGF)POF4-6G3$$1G:(DE-HGF)POF4-6G0$$2G:(DE-HGF)POF4-600$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bForschungsbereich Materie$$lGroßgeräte: Materie$$vPETRA III (DESY)$$x0
000491342 9141_ $$y2023
000491342 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-10
000491342 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-10
000491342 915__ $$0LIC:(DE-HGF)CCBYNCND4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
000491342 915__ $$0StatID:(DE-HGF)1200$$2StatID$$aDBCoverage$$bChemical Reactions$$d2022-11-10
000491342 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-10
000491342 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000491342 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-22$$wger
000491342 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-22
000491342 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-22
000491342 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-22
000491342 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-22
000491342 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-22
000491342 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-22
000491342 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBIOORGAN MED CHEM : 2022$$d2023-10-22
000491342 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-22
000491342 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-22
000491342 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-22
000491342 9201_ $$0I:(DE-H253)EMBL-User-20120814$$kEMBL-User$$lEMBL-User$$x0
000491342 980__ $$ajournal
000491342 980__ $$aVDB
000491342 980__ $$aUNRESTRICTED
000491342 980__ $$aI:(DE-H253)EMBL-User-20120814
000491342 9801_ $$aFullTexts